Summary
The experience that the supplementation of depleted dopamine in the nigro-striatal system of parkinsonian patients with L-dopa improves the clinical triad, akinesia, rigidity and tremor, mainly applies to long-term treatment in the early phase of Parkinson’s disease. Complications in motor performance, like on-off response, wearing-off phenomena, peak-dose dyskinesia, biphasic dyskinesia, off-period dystonia and others, after more than 3 to 5 years following the onset of treatment indicate fluctuations in the dopaminergic feedback control system. It is suggested that these complications are due to progressive presynaptic degeneration and late changes in postsynaptic receptor amplification. However, as fluctuations are not imperative in all patients, an important additional aspect seems to be the topography of denervation, which involves different portions of the striatum to varying degrees. Location and extent of denervation are criteria which appear to have predictive value for the malignancy of the disease, the therapeutic response of drugs and complications in long-term treatment.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Birkmayer W, Riederer P, Youdim MBH (1979) Distinction between benign and malignant type of Parkinson’s disease. Clin Neurol Neurosurg 158: 81–83
Birkmayer W, Riederer P (1985) Die Parkinson-Krankheit, 2nd edn. Springer, Wien New York
Brücke T, Danielczyk W, Simanyi M, Sofie E, Riederer P (1987) Terguride: partial dopamine agonist in the treatment of Parkinson’s disease. In: Yahr MD, Bergmann KJ (eds) Advances in neurology. Raven Press, New York, pp 573–576
Carlsson A (1983) Are “On-off” effects during chronic L-dopa treatment due to faulty feedback control of the nigrostriatal dopamine pathway? J Neural Transm [Suppl] 19: 153–161
Clark D, Hjorth S, Carlsson A (1985) Dopamine receptor agonists: mechanisms underlying autoreceptor selectivity. J Neural Transm 62: 171–207
Corsini GU, Horowski R, Reiner E, del Zompo M (1984) Treatment of Parkinson’s disease with a dopamine partial agonist. Clin Neuropharmacol 7: 950–951
Danielczyk W (1973) Die Behandlung von akinetischen Krisen. Med Welt 24: 1278–1282
Goldstein M, Lieberman A, Meiler E (1985) A possible molecular mechanism for the antiparkinsonian action of bromocriptine in combination with levodopa. TIPS (Nov.) 436–437
Guttman M, Seeman P, Reynolds GP, Riederer P, Jellinger K, Tourtellotte WW (1986) Dopamine D 2 receptor density remains constant in treated Parkinson’s disease. Ann Neurol 19: 487–492
Hardie RJ, Malcolm SL, Lees AJ, Stern GM, Allen JG (1986) The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson’s disease who exhibit on-off fluctuations. Br J Clin Pharmacol 22: 429–436
Hornykiewicz O, Kish SJ (1986) Biochemical pathophysiology of Parkinson’s disease. In: Yahr MD, Bergmann KJ (eds) Advances in neurology. Raven Press, New York, pp 19–34
Jellinger K (1986) Overview of morphological changes in Parkinson’s disease. In: Yahr MD, Bergmann KJ (eds) Advances in neurology. Raven Press, New York, pp 1–18
Kapfhammer HP, Kuss HJ, Eben E, Rüther E (1985) L-dopa infusion experiments in combination with the L-dopa-decarboxylase inhibitors benserazide and carbidopa: L- dopa metabolism and neuroendocrinological effects. Pharmacopsychiat 18: 143–144
Karobath M (1985) Neue Aspekte in der Pharmakotherapie des M. Parkinson. In: Schna- berth G, Auff E (eds) Das Parkinson-Syndrom. Proceedings, Symposium 1984. Wissenschaftlicher Dienst “Roche”, Basle, pp 211–216
Kebabian JW, Calne DB (1979) Multiple receptors for dopamine. Nature 277: 93–96
Marsden CD, Parkes JD, Quinn N (1982) Fluctuations of disability in Parkinson’s disease: clinical aspects. In: Marsden CD, Fahn S (eds) Movement disorders. Butterworth, London, pp 86–122
Muenter MD, Sharpless NS, Tyce GM, Darley L (1977) Patterns of dystonia (“I-D-I” and “D-I-D”) in response to L-dopa therapy of Parkinson’s disease. Mayo Clin Proc 52: 163–174
Poewe WH, Lees AJ, Stern GM (1986) Treatment of motor fluctuations in Parkinson’s disease with an oral sustained-release preparation of L-dopa: clinical and pharmacokinetic observations. Clin Neuropharmacol 9: 430–439
Riederer P, Rausch WD, Birkmayer W, Jellinger K, Seeman D (1978) CNS modulation of adrenal tyrosine hydroxylase in Parkinson’s disease and metabolic encephalopathies. J Neural Transm [Suppl] 14: 121–132
Riederer P (1986) Neurobiochemische Aspekte zur Progression der Parkinson-Krankheit: Post-mortem Befunde und MPTP-Modell. In: Fischer PA (ed) Spätsyndrome der Parkinson-Krankheit. Proceedings, Parkinson-Symposium 1986, Frankfurt. Wissenschaftlicher Dienst “Roche”, Basle, pp 37–48
Rinne UK (1986) The importance of an early combination of a dopamine agonist and levodopa in the treatment of Parkinson’s disease. In: Van Manen J, Rinne UK (eds) Lisuride: a new dopamine agonist and Parkinson’s disease. Proceedings of a symposium, Berlin 1985. Excerpta Medica, Amsterdam, pp 64–71
Seeman P (1980) Brain dopamine receptors. Pharmacol Rev 32: 229–313
Seeman P, Guan HC, Bergeron C, Reynolds GP, Bird ED, Riederer P, Jellinger K, Tourtellotte WW (1987) Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer’s, Parkinson’s, and Huntington’s diseases. Neuropsychopharmacology, in press
Wesemann W (1984) Aspekte zum Wirkmechanismus von Amantadin. In: Danielczyk W, Wesemann W (eds) Amantadin-Workshop. Edition Materia Medica, Socio-Medico Verlag, Gräfelfing
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer-Verlag
About this paper
Cite this paper
Riederer, P. (1988). Factors contributing to fluctuations of the dopaminergic nigro-striatal feedback system in Parkinson’s disease. In: Obeso, J.A., Horowski, R., Marsden, C.D. (eds) Continuous Dopaminergic Stimulation in Parkinson’s Disease. Journal of Neural Transmission, vol 27. Springer, Vienna. https://doi.org/10.1007/978-3-7091-8954-2_16
Download citation
DOI: https://doi.org/10.1007/978-3-7091-8954-2_16
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-82034-6
Online ISBN: 978-3-7091-8954-2
eBook Packages: Springer Book Archive